Stem definition | Drug id | CAS RN |
---|---|---|
androgens/anabolic steroids | 2607 | 58-22-0 |
Dose | Unit | Route |
---|---|---|
0.12 | g | O |
18 | mg | P |
0.12 | g | R |
60 | mg | SL |
50 | mg | TD |
3 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.02 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.97 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 4 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.35 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 24.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.17 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 13, 1972 | FDA | ACTIENT PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood testosterone increased | 291.11 | 20.64 | 40 | 3410 | 110 | 50601564 |
Accidental exposure to product | 201.81 | 20.64 | 71 | 3379 | 22986 | 50578688 |
Virilism | 157.57 | 20.64 | 20 | 3430 | 21 | 50601653 |
Expulsion of medication | 140.27 | 20.64 | 17 | 3433 | 7 | 50601667 |
Enlarged clitoris | 130.86 | 20.64 | 20 | 3430 | 136 | 50601538 |
Precocious puberty | 117.16 | 20.64 | 19 | 3431 | 197 | 50601477 |
Hair growth abnormal | 109.39 | 20.64 | 27 | 3423 | 2534 | 50599140 |
Accidental exposure to product by child | 70.81 | 20.64 | 16 | 3434 | 1024 | 50600650 |
Off label use | 70.81 | 20.64 | 120 | 3330 | 474306 | 50127368 |
Metaplasia | 48.55 | 20.64 | 10 | 3440 | 412 | 50601262 |
Adnexal torsion | 47.71 | 20.64 | 9 | 3441 | 234 | 50601440 |
Hirsutism | 44.97 | 20.64 | 11 | 3439 | 992 | 50600682 |
Skin laceration | 44.71 | 20.64 | 23 | 3427 | 18819 | 50582855 |
Idiopathic intracranial hypertension | 44.34 | 20.64 | 13 | 3437 | 2336 | 50599338 |
Apocrine breast carcinoma | 42.97 | 20.64 | 5 | 3445 | 0 | 50601674 |
Atherosclerotic plaque rupture | 42.97 | 20.64 | 5 | 3445 | 0 | 50601674 |
Priapism | 42.77 | 20.64 | 7 | 3443 | 77 | 50601597 |
Renal infarct | 41.65 | 20.64 | 11 | 3439 | 1349 | 50600325 |
Borderline serous tumour of ovary | 39.51 | 20.64 | 5 | 3445 | 5 | 50601669 |
Self-destructive behaviour | 39.51 | 20.64 | 5 | 3445 | 5 | 50601669 |
Infertility | 39.40 | 20.64 | 9 | 3441 | 604 | 50601070 |
Ovarian endometrioid carcinoma | 38.59 | 20.64 | 5 | 3445 | 7 | 50601667 |
Hormone level abnormal | 36.67 | 20.64 | 11 | 3439 | 2138 | 50599536 |
Vaginal disorder | 33.16 | 20.64 | 8 | 3442 | 681 | 50600993 |
Acne | 32.82 | 20.64 | 19 | 3431 | 19576 | 50582098 |
Blood testosterone decreased | 31.27 | 20.64 | 5 | 3445 | 47 | 50601627 |
Renal artery fibromuscular dysplasia | 30.71 | 20.64 | 4 | 3446 | 6 | 50601668 |
Intraductal proliferative breast lesion | 30.71 | 20.64 | 10 | 3440 | 2540 | 50599134 |
Vocal cord atrophy | 29.37 | 20.64 | 4 | 3446 | 10 | 50601664 |
Dissociative identity disorder | 28.99 | 20.64 | 5 | 3445 | 77 | 50601597 |
Performance enhancing product use | 28.36 | 20.64 | 4 | 3446 | 14 | 50601660 |
Papilloedema | 27.68 | 20.64 | 10 | 3440 | 3463 | 50598211 |
Chorioretinopathy | 26.82 | 20.64 | 7 | 3443 | 819 | 50600855 |
Ovarian necrosis | 26.32 | 20.64 | 4 | 3446 | 26 | 50601648 |
Gender dysphoria | 25.78 | 20.64 | 3 | 3447 | 0 | 50601674 |
Ovarian cancer stage II | 25.48 | 20.64 | 4 | 3446 | 33 | 50601641 |
Product packaging difficult to open | 23.68 | 20.64 | 4 | 3446 | 54 | 50601620 |
Focal segmental glomerulosclerosis | 23.47 | 20.64 | 7 | 3443 | 1334 | 50600340 |
Breast cancer | 23.37 | 20.64 | 21 | 3429 | 42869 | 50558805 |
Osteonecrosis | 23.07 | 20.64 | 16 | 3434 | 22501 | 50579173 |
Growth accelerated | 21.89 | 20.64 | 3 | 3447 | 8 | 50601666 |
Product quality issue | 20.66 | 20.64 | 17 | 3433 | 30841 | 50570833 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood testosterone decreased | 634.76 | 11.48 | 218 | 33386 | 3712 | 29537211 |
Blood testosterone increased | 503.42 | 11.48 | 133 | 33471 | 855 | 29540068 |
Polycythaemia | 298.18 | 11.48 | 101 | 33503 | 1643 | 29539280 |
Product administered at inappropriate site | 256.75 | 11.48 | 90 | 33514 | 1630 | 29539293 |
Product deposit | 251.63 | 11.48 | 60 | 33544 | 235 | 29540688 |
Application site rash | 233.85 | 11.48 | 69 | 33535 | 695 | 29540228 |
Deep vein thrombosis | 190.96 | 11.48 | 278 | 33326 | 57121 | 29483802 |
Expulsion of medication | 172.06 | 11.48 | 32 | 33572 | 16 | 29540907 |
Blood testosterone abnormal | 163.71 | 11.48 | 43 | 33561 | 269 | 29540654 |
Incorrect dose administered | 159.51 | 11.48 | 192 | 33412 | 32792 | 29508131 |
Precocious puberty | 140.02 | 11.48 | 32 | 33572 | 99 | 29540824 |
Haematocrit increased | 137.65 | 11.48 | 57 | 33547 | 1651 | 29539272 |
Product quality issue | 127.37 | 11.48 | 121 | 33483 | 15774 | 29525149 |
Poor quality product administered | 123.65 | 11.48 | 52 | 33552 | 1567 | 29539356 |
Application site pain | 121.82 | 11.48 | 52 | 33552 | 1627 | 29539296 |
Implant site pain | 116.84 | 11.48 | 27 | 33577 | 89 | 29540834 |
Pulmonary embolism | 116.60 | 11.48 | 264 | 33340 | 76270 | 29464653 |
Application site erythema | 113.78 | 11.48 | 53 | 33551 | 2046 | 29538877 |
Prescribed overdose | 108.00 | 11.48 | 85 | 33519 | 8598 | 29532325 |
Testicular atrophy | 104.59 | 11.48 | 34 | 33570 | 483 | 29540440 |
Toxicity to various agents | 103.93 | 11.48 | 34 | 33570 | 173627 | 29367296 |
Multiple use of single-use product | 86.35 | 11.48 | 24 | 33580 | 191 | 29540732 |
Insulin-like growth factor increased | 85.90 | 11.48 | 36 | 33568 | 1075 | 29539848 |
Infertility male | 85.08 | 11.48 | 23 | 33581 | 163 | 29540760 |
Application site pruritus | 83.75 | 11.48 | 37 | 33567 | 1260 | 29539663 |
Death | 77.99 | 11.48 | 171 | 33433 | 341913 | 29199010 |
Product odour abnormal | 77.55 | 11.48 | 29 | 33575 | 636 | 29540287 |
Product packaging quantity issue | 77.12 | 11.48 | 30 | 33574 | 735 | 29540188 |
Libido decreased | 75.92 | 11.48 | 52 | 33552 | 4246 | 29536677 |
Pituitary tumour benign | 72.84 | 11.48 | 29 | 33575 | 757 | 29540166 |
Device delivery system issue | 71.79 | 11.48 | 23 | 33581 | 311 | 29540612 |
Application site reaction | 70.85 | 11.48 | 24 | 33580 | 390 | 29540533 |
Injection site pain | 70.83 | 11.48 | 130 | 33474 | 32316 | 29508607 |
Oestradiol increased | 69.89 | 11.48 | 16 | 33588 | 50 | 29540873 |
Clear cell renal cell carcinoma | 68.92 | 11.48 | 30 | 33574 | 985 | 29539938 |
Blood testosterone free decreased | 67.43 | 11.48 | 16 | 33588 | 61 | 29540862 |
Febrile neutropenia | 67.04 | 11.48 | 22 | 33582 | 112218 | 29428705 |
Neutropenia | 66.97 | 11.48 | 33 | 33571 | 131678 | 29409245 |
Craniopharyngioma | 66.37 | 11.48 | 21 | 33583 | 272 | 29540651 |
Erectile dysfunction | 62.37 | 11.48 | 89 | 33515 | 17920 | 29523003 |
Device expulsion | 62.35 | 11.48 | 14 | 33590 | 39 | 29540884 |
Gynaecomastia | 61.00 | 11.48 | 60 | 33544 | 8157 | 29532766 |
Application site exfoliation | 57.08 | 11.48 | 15 | 33589 | 94 | 29540829 |
General physical health deterioration | 56.61 | 11.48 | 23 | 33581 | 102834 | 29438089 |
Feeling abnormal | 55.97 | 11.48 | 162 | 33442 | 54283 | 29486640 |
Secondary hypogonadism | 54.59 | 11.48 | 18 | 33586 | 268 | 29540655 |
Product dose omission issue | 54.18 | 11.48 | 235 | 33369 | 96148 | 29444775 |
Application site irritation | 53.95 | 11.48 | 22 | 33582 | 612 | 29540311 |
Haemoglobin increased | 53.55 | 11.48 | 36 | 33568 | 2850 | 29538073 |
Prostatic specific antigen increased | 52.46 | 11.48 | 68 | 33536 | 12496 | 29528427 |
Azoospermia | 52.16 | 11.48 | 19 | 33585 | 386 | 29540537 |
Mesenteric vein thrombosis | 51.88 | 11.48 | 20 | 33584 | 478 | 29540445 |
Osteonecrosis | 51.57 | 11.48 | 70 | 33534 | 13449 | 29527474 |
Application site dryness | 51.38 | 11.48 | 12 | 33592 | 42 | 29540881 |
Sleep apnoea syndrome | 50.97 | 11.48 | 80 | 33524 | 17519 | 29523404 |
Completed suicide | 49.95 | 11.48 | 20 | 33584 | 90226 | 29450697 |
Muscle mass | 49.83 | 11.48 | 16 | 33588 | 218 | 29540705 |
Thrombocytopenia | 49.65 | 11.48 | 48 | 33556 | 134775 | 29406148 |
Hypogonadism | 49.12 | 11.48 | 27 | 33577 | 1484 | 29539439 |
Pyrexia | 48.75 | 11.48 | 166 | 33438 | 287456 | 29253467 |
Hair growth abnormal | 47.92 | 11.48 | 21 | 33583 | 701 | 29540222 |
Application site vesicles | 46.78 | 11.48 | 19 | 33585 | 523 | 29540400 |
Red blood cell count increased | 45.60 | 11.48 | 25 | 33579 | 1367 | 29539556 |
Wrong technique in product usage process | 45.11 | 11.48 | 106 | 33498 | 31322 | 29509601 |
Product container issue | 45.00 | 11.48 | 19 | 33585 | 578 | 29540345 |
Acute myocardial infarction | 44.00 | 11.48 | 138 | 33466 | 48300 | 29492623 |
Liquid product physical issue | 43.74 | 11.48 | 16 | 33588 | 329 | 29540594 |
Implant site bruising | 43.71 | 11.48 | 8 | 33596 | 3 | 29540920 |
Anaemia | 43.57 | 11.48 | 103 | 33501 | 200848 | 29340075 |
Lymphoproliferative disorder | 43.28 | 11.48 | 30 | 33574 | 2497 | 29538426 |
Performance enhancing product use | 43.00 | 11.48 | 11 | 33593 | 61 | 29540862 |
Hyperoestrogenism | 42.37 | 11.48 | 8 | 33596 | 5 | 29540918 |
Focal segmental glomerulosclerosis | 42.07 | 11.48 | 26 | 33578 | 1781 | 29539142 |
Implant site infection | 41.68 | 11.48 | 21 | 33583 | 965 | 29539958 |
Blood oestrogen increased | 40.46 | 11.48 | 10 | 33594 | 47 | 29540876 |
Thrombosis | 40.35 | 11.48 | 124 | 33480 | 42921 | 29498002 |
Insulin-like growth factor decreased | 39.85 | 11.48 | 14 | 33590 | 255 | 29540668 |
Drug interaction | 39.80 | 11.48 | 105 | 33499 | 197280 | 29343643 |
Application site discolouration | 38.39 | 11.48 | 13 | 33591 | 211 | 29540712 |
Headache | 37.54 | 11.48 | 331 | 33273 | 173676 | 29367247 |
Acne | 37.09 | 11.48 | 49 | 33555 | 9171 | 29531752 |
Pancytopenia | 36.33 | 11.48 | 25 | 33579 | 83143 | 29457780 |
Cerebrovascular accident | 36.14 | 11.48 | 178 | 33426 | 76733 | 29464190 |
Infertility | 35.83 | 11.48 | 12 | 33592 | 188 | 29540735 |
Depression | 35.79 | 11.48 | 191 | 33413 | 84956 | 29455967 |
Interstitial lung disease | 34.99 | 11.48 | 11 | 33593 | 57707 | 29483216 |
Acute kidney injury | 34.89 | 11.48 | 169 | 33435 | 265098 | 29275825 |
Acne fulminans | 34.73 | 11.48 | 11 | 33593 | 143 | 29540780 |
Spinal cord abscess | 34.60 | 11.48 | 12 | 33592 | 210 | 29540713 |
Product physical consistency issue | 34.58 | 11.48 | 14 | 33590 | 382 | 29540541 |
Septic shock | 34.39 | 11.48 | 14 | 33590 | 62546 | 29478377 |
Portal vein thrombosis | 34.01 | 11.48 | 29 | 33575 | 3280 | 29537643 |
Product physical issue | 33.92 | 11.48 | 24 | 33580 | 2064 | 29538859 |
Product administration error | 33.33 | 11.48 | 59 | 33545 | 14251 | 29526672 |
Myocardial infarction | 33.33 | 11.48 | 227 | 33377 | 110069 | 29430854 |
Breast cancer | 32.98 | 11.48 | 12 | 33592 | 243 | 29540680 |
Application site urticaria | 32.91 | 11.48 | 9 | 33595 | 67 | 29540856 |
Prostate cancer | 32.27 | 11.48 | 82 | 33522 | 25445 | 29515478 |
Drug abuse | 32.09 | 11.48 | 177 | 33427 | 79706 | 29461217 |
Product storage error | 31.79 | 11.48 | 38 | 33566 | 6432 | 29534491 |
Drug ineffective | 30.87 | 11.48 | 581 | 33023 | 362589 | 29178334 |
Blood follicle stimulating hormone decreased | 30.74 | 11.48 | 8 | 33596 | 48 | 29540875 |
Fatigue | 30.13 | 11.48 | 516 | 33088 | 316305 | 29224618 |
Blood testosterone free increased | 29.64 | 11.48 | 7 | 33597 | 26 | 29540897 |
Blood luteinising hormone decreased | 28.99 | 11.48 | 9 | 33595 | 109 | 29540814 |
Virilism | 28.91 | 11.48 | 5 | 33599 | 0 | 29540923 |
Implant site swelling | 28.75 | 11.48 | 8 | 33596 | 64 | 29540859 |
Expired product administered | 27.60 | 11.48 | 24 | 33580 | 2787 | 29538136 |
Muscle hypertrophy | 27.49 | 11.48 | 7 | 33597 | 38 | 29540885 |
Stubbornness | 26.91 | 11.48 | 6 | 33598 | 16 | 29540907 |
Implant site haemorrhage | 26.15 | 11.48 | 8 | 33596 | 92 | 29540831 |
Left ventricular hypertrophy | 26.01 | 11.48 | 35 | 33569 | 6668 | 29534255 |
Coronary artery disease | 25.75 | 11.48 | 109 | 33495 | 44081 | 29496842 |
Pneumonia | 25.48 | 11.48 | 237 | 33367 | 319935 | 29220988 |
Drug-disease interaction | 25.39 | 11.48 | 11 | 33593 | 357 | 29540566 |
Renal infarct | 25.30 | 11.48 | 16 | 33588 | 1141 | 29539782 |
Malignant neoplasm progression | 25.23 | 11.48 | 28 | 33576 | 73831 | 29467092 |
Melaena | 25.03 | 11.48 | 3 | 33601 | 31173 | 29509750 |
Leukopenia | 24.90 | 11.48 | 16 | 33588 | 55187 | 29485736 |
Pituitary tumour | 24.88 | 11.48 | 12 | 33592 | 501 | 29540422 |
Platelet count decreased | 24.82 | 11.48 | 51 | 33553 | 104621 | 29436302 |
Therapeutic response unexpected | 24.63 | 11.48 | 39 | 33565 | 8599 | 29532324 |
Pituitary tumour recurrent | 24.62 | 11.48 | 7 | 33597 | 61 | 29540862 |
Acromegaly | 24.31 | 11.48 | 6 | 33598 | 28 | 29540895 |
Hyperhidrosis | 23.93 | 11.48 | 140 | 33464 | 64400 | 29476523 |
Disease progression | 23.89 | 11.48 | 35 | 33569 | 81881 | 29459042 |
Multiple organ dysfunction syndrome | 23.76 | 11.48 | 22 | 33582 | 63094 | 29477829 |
Incorrect product administration duration | 23.68 | 11.48 | 26 | 33578 | 4015 | 29536908 |
Hypercoagulation | 23.63 | 11.48 | 15 | 33589 | 1077 | 29539846 |
Idiopathic intracranial hypertension | 23.19 | 11.48 | 12 | 33592 | 583 | 29540340 |
Anger | 22.95 | 11.48 | 43 | 33561 | 10847 | 29530076 |
Application site dermatitis | 22.78 | 11.48 | 6 | 33598 | 38 | 29540885 |
Hypotension | 22.61 | 11.48 | 129 | 33475 | 194225 | 29346698 |
Hormone level abnormal | 22.59 | 11.48 | 10 | 33594 | 342 | 29540581 |
Cholelithiasis | 22.58 | 11.48 | 59 | 33545 | 18613 | 29522310 |
Implant site erythema | 22.38 | 11.48 | 6 | 33598 | 41 | 29540882 |
Intentional overdose | 22.20 | 11.48 | 8 | 33596 | 38520 | 29502403 |
Phaeochromocytoma | 22.03 | 11.48 | 8 | 33596 | 161 | 29540762 |
Hypogonadism male | 21.72 | 11.48 | 9 | 33595 | 261 | 29540662 |
Neoplasm recurrence | 21.71 | 11.48 | 18 | 33586 | 1959 | 29538964 |
Pre-existing condition improved | 21.65 | 11.48 | 19 | 33585 | 2234 | 29538689 |
Insulin resistance | 21.48 | 11.48 | 11 | 33593 | 523 | 29540400 |
Loss of libido | 21.34 | 11.48 | 19 | 33585 | 2277 | 29538646 |
Decreased appetite | 21.21 | 11.48 | 89 | 33515 | 145253 | 29395670 |
C-reactive protein increased | 21.12 | 11.48 | 12 | 33592 | 44251 | 29496672 |
Renal artery thrombosis | 20.95 | 11.48 | 9 | 33595 | 286 | 29540637 |
Product complaint | 20.63 | 11.48 | 28 | 33576 | 5377 | 29535546 |
Aortic aneurysm | 20.45 | 11.48 | 30 | 33574 | 6190 | 29534733 |
Sepsis | 20.44 | 11.48 | 88 | 33516 | 142594 | 29398329 |
Intentional product misuse | 19.81 | 11.48 | 85 | 33519 | 34576 | 29506347 |
Application site paraesthesia | 19.47 | 11.48 | 4 | 33600 | 6 | 29540917 |
Glucose tolerance decreased | 19.30 | 11.48 | 6 | 33598 | 73 | 29540850 |
Underdose | 19.21 | 11.48 | 42 | 33562 | 11827 | 29529096 |
Mucosal inflammation | 19.18 | 11.48 | 6 | 33598 | 31589 | 29509334 |
Treatment failure | 19.13 | 11.48 | 9 | 33595 | 36930 | 29503993 |
Prostatomegaly | 19.10 | 11.48 | 25 | 33579 | 4636 | 29536287 |
Oligospermia | 19.08 | 11.48 | 6 | 33598 | 76 | 29540847 |
Irritability | 19.08 | 11.48 | 62 | 33542 | 22090 | 29518833 |
Myocardial fibrosis | 19.04 | 11.48 | 13 | 33591 | 1055 | 29539868 |
Needle issue | 19.01 | 11.48 | 25 | 33579 | 4658 | 29536265 |
Bone marrow failure | 18.99 | 11.48 | 4 | 33600 | 27445 | 29513478 |
Blood thyroid stimulating hormone decreased | 18.98 | 11.48 | 16 | 33588 | 1782 | 29539141 |
Renal failure | 18.97 | 11.48 | 70 | 33534 | 118529 | 29422394 |
Product colour issue | 18.93 | 11.48 | 9 | 33595 | 364 | 29540559 |
No adverse event | 18.90 | 11.48 | 53 | 33551 | 17425 | 29523498 |
Cardiac death | 18.62 | 11.48 | 12 | 33592 | 884 | 29540039 |
Accidental exposure to product by child | 18.46 | 11.48 | 14 | 33590 | 1340 | 29539583 |
Implant site mass | 18.42 | 11.48 | 4 | 33600 | 9 | 29540914 |
Breast tenderness | 18.41 | 11.48 | 11 | 33593 | 709 | 29540214 |
Amnesia | 18.28 | 11.48 | 62 | 33542 | 22581 | 29518342 |
Testicular pain | 18.02 | 11.48 | 18 | 33586 | 2491 | 29538432 |
Blood growth hormone increased | 17.90 | 11.48 | 8 | 33596 | 280 | 29540643 |
Chorioretinopathy | 17.90 | 11.48 | 14 | 33590 | 1402 | 29539521 |
Acne conglobata | 17.85 | 11.48 | 4 | 33600 | 11 | 29540912 |
Application site inflammation | 17.57 | 11.48 | 6 | 33598 | 100 | 29540823 |
Nipple pain | 17.56 | 11.48 | 10 | 33594 | 589 | 29540334 |
Growth hormone-producing pituitary tumour | 17.44 | 11.48 | 5 | 33599 | 45 | 29540878 |
Anorgasmia | 17.43 | 11.48 | 10 | 33594 | 597 | 29540326 |
Angiofibroma | 17.34 | 11.48 | 3 | 33601 | 0 | 29540923 |
Borderline ovarian tumour | 17.34 | 11.48 | 3 | 33601 | 0 | 29540923 |
Circumstance or information capable of leading to medication error | 16.99 | 11.48 | 14 | 33590 | 1510 | 29539413 |
Cardiac failure | 16.85 | 11.48 | 41 | 33563 | 79246 | 29461677 |
Application site burn | 16.83 | 11.48 | 7 | 33597 | 205 | 29540718 |
Thyroxine decreased | 16.75 | 11.48 | 6 | 33598 | 116 | 29540807 |
Neutrophil count decreased | 16.61 | 11.48 | 15 | 33589 | 43552 | 29497371 |
Oxygen saturation decreased | 16.51 | 11.48 | 16 | 33588 | 44921 | 29496002 |
Growth accelerated | 16.51 | 11.48 | 4 | 33600 | 17 | 29540906 |
Transient ischaemic attack | 16.45 | 11.48 | 61 | 33543 | 23209 | 29517714 |
Confusional state | 16.45 | 11.48 | 82 | 33522 | 127795 | 29413128 |
Stomatitis | 16.40 | 11.48 | 11 | 33593 | 37102 | 29503821 |
Cardio-respiratory arrest | 16.40 | 11.48 | 20 | 33584 | 50581 | 29490342 |
Bradycardia | 16.39 | 11.48 | 31 | 33573 | 65598 | 29475325 |
Gastrointestinal haemorrhage | 16.22 | 11.48 | 42 | 33562 | 79491 | 29461432 |
Implant site cellulitis | 16.15 | 11.48 | 4 | 33600 | 19 | 29540904 |
Skin irritation | 15.37 | 11.48 | 22 | 33582 | 4439 | 29536484 |
Hyperkalaemia | 15.33 | 11.48 | 29 | 33575 | 61363 | 29479560 |
Implant site necrosis | 15.27 | 11.48 | 3 | 33601 | 3 | 29540920 |
Dermal absorption impaired | 15.27 | 11.48 | 3 | 33601 | 3 | 29540920 |
Sperm concentration zero | 15.27 | 11.48 | 3 | 33601 | 3 | 29540920 |
Thyrotoxic periodic paralysis | 15.25 | 11.48 | 5 | 33599 | 73 | 29540850 |
Thyroid mass | 15.03 | 11.48 | 8 | 33596 | 412 | 29540511 |
Testis discomfort | 14.81 | 11.48 | 3 | 33601 | 4 | 29540919 |
Blood cholesterol increased | 14.67 | 11.48 | 45 | 33559 | 15550 | 29525373 |
Small airways disease | 14.48 | 11.48 | 4 | 33600 | 31 | 29540892 |
Device extrusion | 14.41 | 11.48 | 3 | 33601 | 5 | 29540918 |
Asthma exercise induced | 14.29 | 11.48 | 5 | 33599 | 90 | 29540833 |
Androgen deficiency | 14.07 | 11.48 | 6 | 33598 | 187 | 29540736 |
Accidental exposure to product | 14.06 | 11.48 | 35 | 33569 | 10718 | 29530205 |
Implant site rash | 14.06 | 11.48 | 3 | 33601 | 6 | 29540917 |
Penis disorder | 14.03 | 11.48 | 11 | 33593 | 1106 | 29539817 |
Carpal tunnel syndrome | 13.75 | 11.48 | 20 | 33584 | 4094 | 29536829 |
Back pain | 13.73 | 11.48 | 177 | 33427 | 102107 | 29438816 |
Alopecia | 13.47 | 11.48 | 50 | 33554 | 19034 | 29521889 |
Coma | 13.42 | 11.48 | 15 | 33589 | 39435 | 29501488 |
Ophthalmic vein thrombosis | 13.32 | 11.48 | 4 | 33600 | 43 | 29540880 |
Sleep disorder | 13.32 | 11.48 | 59 | 33545 | 24327 | 29516596 |
Hepatic adenoma | 13.15 | 11.48 | 4 | 33600 | 45 | 29540878 |
Electrocardiogram QT prolonged | 13.12 | 11.48 | 13 | 33591 | 36124 | 29504799 |
Gamma-glutamyltransferase increased | 13.11 | 11.48 | 7 | 33597 | 26730 | 29514193 |
Haemoglobin decreased | 13.09 | 11.48 | 71 | 33533 | 108304 | 29432619 |
Empty sella syndrome | 13.07 | 11.48 | 4 | 33600 | 46 | 29540877 |
Retinal vein occlusion | 12.96 | 11.48 | 12 | 33592 | 1513 | 29539410 |
Lower respiratory tract infection | 12.91 | 11.48 | 7 | 33597 | 26495 | 29514428 |
Factor V Leiden mutation | 12.85 | 11.48 | 4 | 33600 | 49 | 29540874 |
Hyponatraemia | 12.83 | 11.48 | 37 | 33567 | 67596 | 29473327 |
Drug withdrawal syndrome | 12.59 | 11.48 | 47 | 33557 | 17937 | 29522986 |
Muscle spasms | 12.56 | 11.48 | 121 | 33483 | 64961 | 29475962 |
Injection site bruising | 12.47 | 11.48 | 27 | 33577 | 7553 | 29533370 |
Cardiomyopathy | 12.39 | 11.48 | 41 | 33563 | 14746 | 29526177 |
Eye colour change | 12.39 | 11.48 | 6 | 33598 | 253 | 29540670 |
Respiratory distress | 12.30 | 11.48 | 11 | 33593 | 32095 | 29508828 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 12.29 | 11.48 | 10 | 33594 | 1060 | 29539863 |
Impulsive behaviour | 12.26 | 11.48 | 13 | 33591 | 1930 | 29538993 |
Cortisol decreased | 12.24 | 11.48 | 9 | 33595 | 822 | 29540101 |
Eosinophilia | 12.10 | 11.48 | 5 | 33599 | 22156 | 29518767 |
Metabolic acidosis | 12.08 | 11.48 | 15 | 33589 | 37647 | 29503276 |
Gastric hypomotility | 12.04 | 11.48 | 4 | 33600 | 61 | 29540862 |
Lactic acidosis | 12.03 | 11.48 | 10 | 33594 | 30237 | 29510686 |
Cerebral venous thrombosis | 11.94 | 11.48 | 8 | 33596 | 630 | 29540293 |
Inappropriate schedule of product administration | 11.93 | 11.48 | 89 | 33515 | 44383 | 29496540 |
Sperm concentration decreased | 11.91 | 11.48 | 5 | 33599 | 150 | 29540773 |
Skin odour abnormal | 11.81 | 11.48 | 9 | 33595 | 867 | 29540056 |
Haematuria | 11.78 | 11.48 | 20 | 33584 | 44119 | 29496804 |
Obesity | 11.75 | 11.48 | 31 | 33573 | 9832 | 29531091 |
Weight increased | 11.73 | 11.48 | 136 | 33468 | 76531 | 29464392 |
Cortisol increased | 11.64 | 11.48 | 5 | 33599 | 159 | 29540764 |
Anxiety | 11.57 | 11.48 | 148 | 33456 | 85217 | 29455706 |
Depressed level of consciousness | 11.55 | 11.48 | 15 | 33589 | 36927 | 29503996 |
Arterial occlusive disease | 11.55 | 11.48 | 18 | 33586 | 3916 | 29537007 |
Pneumonitis | 11.49 | 11.48 | 9 | 33595 | 28035 | 29512888 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood testosterone increased | 549.33 | 11.29 | 113 | 26422 | 673 | 64471524 |
Blood testosterone decreased | 314.24 | 11.29 | 87 | 26448 | 2038 | 64470159 |
Polycythaemia | 301.44 | 11.29 | 83 | 26452 | 1904 | 64470293 |
Expulsion of medication | 232.87 | 11.29 | 36 | 26499 | 14 | 64472183 |
Deep vein thrombosis | 199.84 | 11.29 | 231 | 26304 | 104951 | 64367246 |
Precocious puberty | 190.61 | 11.29 | 40 | 26495 | 266 | 64471931 |
Virilism | 146.67 | 11.29 | 23 | 26512 | 12 | 64472185 |
Pulmonary embolism | 141.71 | 11.29 | 232 | 26303 | 146124 | 64326073 |
Product administered at inappropriate site | 116.53 | 11.29 | 45 | 26490 | 3065 | 64469132 |
Acute myocardial infarction | 101.46 | 11.29 | 134 | 26401 | 69584 | 64402613 |
Haematocrit increased | 99.57 | 11.29 | 41 | 26494 | 3304 | 64468893 |
Idiopathic intracranial hypertension | 98.87 | 11.29 | 38 | 26497 | 2555 | 64469642 |
Application site rash | 94.14 | 11.29 | 34 | 26501 | 1920 | 64470277 |
Blood testosterone abnormal | 92.85 | 11.29 | 20 | 26515 | 153 | 64472044 |
Erectile dysfunction | 89.61 | 11.29 | 59 | 26476 | 12568 | 64459629 |
Testicular atrophy | 89.30 | 11.29 | 22 | 26513 | 320 | 64471877 |
Enlarged clitoris | 84.13 | 11.29 | 13 | 26522 | 5 | 64472192 |
Clear cell renal cell carcinoma | 79.76 | 11.29 | 31 | 26504 | 2148 | 64470049 |
Gynaecomastia | 73.81 | 11.29 | 40 | 26495 | 5976 | 64466221 |
Craniopharyngioma | 71.93 | 11.29 | 19 | 26516 | 370 | 64471827 |
Application site pain | 71.67 | 11.29 | 35 | 26500 | 4213 | 64467984 |
Product deposit | 71.45 | 11.29 | 19 | 26516 | 380 | 64471817 |
Focal segmental glomerulosclerosis | 70.74 | 11.29 | 31 | 26504 | 2913 | 64469284 |
Prostatic specific antigen increased | 69.73 | 11.29 | 44 | 26491 | 8716 | 64463481 |
Product quality issue | 66.03 | 11.29 | 71 | 26464 | 29728 | 64442469 |
Insulin-like growth factor increased | 65.82 | 11.29 | 25 | 26510 | 1627 | 64470570 |
Accidental exposure to product by child | 65.72 | 11.29 | 28 | 26507 | 2457 | 64469740 |
Drug abuse | 63.89 | 11.29 | 157 | 26378 | 132217 | 64339980 |
Secondary hypogonadism | 63.88 | 11.29 | 17 | 26518 | 341 | 64471856 |
Prescribed overdose | 62.73 | 11.29 | 58 | 26477 | 20273 | 64451924 |
Acne fulminans | 61.11 | 11.29 | 14 | 26521 | 146 | 64472051 |
Infertility male | 60.87 | 11.29 | 13 | 26522 | 95 | 64472102 |
Hair growth abnormal | 60.55 | 11.29 | 26 | 26509 | 2326 | 64469871 |
Myocardial infarction | 59.24 | 11.29 | 176 | 26359 | 165645 | 64306552 |
Coronary artery disease | 58.65 | 11.29 | 96 | 26439 | 60337 | 64411860 |
Toxicity to various agents | 58.36 | 11.29 | 39 | 26496 | 363474 | 64108723 |
Renal infarct | 56.68 | 11.29 | 25 | 26510 | 2386 | 64469811 |
Oestradiol increased | 56.39 | 11.29 | 12 | 26523 | 86 | 64472111 |
Product odour abnormal | 55.31 | 11.29 | 20 | 26515 | 1133 | 64471064 |
Pituitary tumour benign | 54.63 | 11.29 | 24 | 26511 | 2269 | 64469928 |
Lymphoproliferative disorder | 54.58 | 11.29 | 31 | 26504 | 5072 | 64467125 |
Application site erythema | 54.27 | 11.29 | 30 | 26505 | 4659 | 64467538 |
Completed suicide | 52.03 | 11.29 | 14 | 26521 | 224400 | 64247797 |
Osteonecrosis | 51.84 | 11.29 | 61 | 26474 | 28168 | 64444029 |
Cerebrovascular accident | 49.10 | 11.29 | 146 | 26389 | 137437 | 64334760 |
Thrombosis | 47.86 | 11.29 | 96 | 26439 | 70546 | 64401651 |
Left ventricular hypertrophy | 47.84 | 11.29 | 36 | 26499 | 9470 | 64462727 |
Portal vein thrombosis | 47.22 | 11.29 | 28 | 26507 | 4963 | 64467234 |
Prostate cancer | 47.11 | 11.29 | 49 | 26486 | 19746 | 64452451 |
Accidental exposure to product | 46.81 | 11.29 | 56 | 26479 | 26308 | 64445889 |
Performance enhancing product use | 46.14 | 11.29 | 10 | 26525 | 79 | 64472118 |
Hypogonadism | 46.11 | 11.29 | 17 | 26518 | 1018 | 64471179 |
Mesenteric vein thrombosis | 45.81 | 11.29 | 18 | 26517 | 1284 | 64470913 |
Libido decreased | 45.69 | 11.29 | 27 | 26508 | 4757 | 64467440 |
Neutropenia | 45.22 | 11.29 | 21 | 26514 | 239603 | 64232594 |
Application site pruritus | 44.72 | 11.29 | 24 | 26511 | 3515 | 64468682 |
Muscle mass | 43.56 | 11.29 | 13 | 26522 | 400 | 64471797 |
Chorioretinopathy | 42.85 | 11.29 | 20 | 26515 | 2177 | 64470020 |
Ovarian endometrioid carcinoma | 41.37 | 11.29 | 7 | 26528 | 10 | 64472187 |
Haemoglobin increased | 41.08 | 11.29 | 26 | 26509 | 5175 | 64467022 |
General physical health deterioration | 38.43 | 11.29 | 18 | 26517 | 204407 | 64267790 |
Implant site infection | 38.25 | 11.29 | 17 | 26518 | 1652 | 64470545 |
Ophthalmic vein thrombosis | 37.46 | 11.29 | 10 | 26525 | 203 | 64471994 |
Spinal cord abscess | 36.36 | 11.29 | 11 | 26524 | 355 | 64471842 |
Blood oestrogen increased | 35.41 | 11.29 | 8 | 26527 | 78 | 64472119 |
Oligospermia | 34.90 | 11.29 | 6 | 26529 | 10 | 64472187 |
Acne | 34.53 | 11.29 | 45 | 26490 | 23036 | 64449161 |
Priapism | 34.27 | 11.29 | 21 | 26514 | 3949 | 64468248 |
Apocrine breast carcinoma | 33.98 | 11.29 | 5 | 26530 | 0 | 64472197 |
Atherosclerotic plaque rupture | 33.98 | 11.29 | 5 | 26530 | 0 | 64472197 |
Sleep apnoea syndrome | 33.95 | 11.29 | 51 | 26484 | 29781 | 64442416 |
Growth accelerated | 33.87 | 11.29 | 6 | 26529 | 13 | 64472184 |
Red blood cell count increased | 33.78 | 11.29 | 20 | 26515 | 3535 | 64468662 |
Rheumatoid arthritis | 33.22 | 11.29 | 13 | 26522 | 164281 | 64307916 |
Febrile neutropenia | 33.06 | 11.29 | 18 | 26517 | 187639 | 64284558 |
Implant site haemorrhage | 32.65 | 11.29 | 9 | 26526 | 207 | 64471990 |
Incorrect dose administered | 32.45 | 11.29 | 75 | 26460 | 60690 | 64411507 |
Metaplasia | 30.92 | 11.29 | 10 | 26525 | 403 | 64471794 |
Borderline serous tumour of ovary | 30.52 | 11.29 | 5 | 26530 | 5 | 64472192 |
Poor quality product administered | 30.32 | 11.29 | 18 | 26517 | 3197 | 64469000 |
Neoplasm recurrence | 30.31 | 11.29 | 19 | 26516 | 3720 | 64468477 |
Aortic aneurysm | 30.18 | 11.29 | 25 | 26510 | 7549 | 64464648 |
Blood luteinising hormone decreased | 30.13 | 11.29 | 8 | 26527 | 159 | 64472038 |
Implant site pain | 30.10 | 11.29 | 15 | 26520 | 1885 | 64470312 |
Irritability | 29.90 | 11.29 | 54 | 26481 | 36692 | 64435505 |
Blood testosterone free increased | 29.61 | 11.29 | 5 | 26530 | 7 | 64472190 |
Feeling abnormal | 29.53 | 11.29 | 121 | 26414 | 133481 | 64338716 |
Blood follicle stimulating hormone decreased | 29.50 | 11.29 | 7 | 26528 | 86 | 64472111 |
Application site vesicles | 28.81 | 11.29 | 13 | 26522 | 1309 | 64470888 |
Infertility | 28.63 | 11.29 | 10 | 26525 | 512 | 64471685 |
Blood testosterone free decreased | 28.45 | 11.29 | 6 | 26529 | 41 | 64472156 |
Drug-disease interaction | 28.33 | 11.29 | 11 | 26524 | 760 | 64471437 |
Product administration error | 28.29 | 11.29 | 45 | 26490 | 27598 | 64444599 |
Depression | 27.99 | 11.29 | 149 | 26386 | 183142 | 64289055 |
Muscle hypertrophy | 27.62 | 11.29 | 7 | 26528 | 115 | 64472082 |
Treatment failure | 27.61 | 11.29 | 7 | 26528 | 116809 | 64355388 |
Product dose omission issue | 27.51 | 11.29 | 155 | 26380 | 194592 | 64277605 |
Vocal cord atrophy | 27.31 | 11.29 | 5 | 26530 | 14 | 64472183 |
Multiple use of single-use product | 27.23 | 11.29 | 10 | 26525 | 592 | 64471605 |
Anger | 27.23 | 11.29 | 33 | 26502 | 15708 | 64456489 |
Pituitary tumour recurrent | 26.91 | 11.29 | 7 | 26528 | 128 | 64472069 |
Myocardial fibrosis | 26.60 | 11.29 | 13 | 26522 | 1567 | 64470630 |
Contraindicated product administered | 26.39 | 11.29 | 6 | 26529 | 107823 | 64364374 |
Azoospermia | 26.23 | 11.29 | 7 | 26528 | 142 | 64472055 |
Hormone level abnormal | 25.57 | 11.29 | 13 | 26522 | 1704 | 64470493 |
Glucose tolerance decreased | 25.12 | 11.29 | 6 | 26529 | 76 | 64472121 |
Application site exfoliation | 24.72 | 11.29 | 8 | 26527 | 323 | 64471874 |
Self-destructive behaviour | 24.42 | 11.29 | 4 | 26531 | 4 | 64472193 |
Adnexal torsion | 24.36 | 11.29 | 7 | 26528 | 188 | 64472009 |
Insulin-like growth factor decreased | 24.25 | 11.29 | 9 | 26526 | 549 | 64471648 |
Penis disorder | 24.14 | 11.29 | 10 | 26525 | 818 | 64471379 |
Loss of libido | 24.09 | 11.29 | 14 | 26521 | 2390 | 64469807 |
Hyperandrogenism | 23.52 | 11.29 | 4 | 26531 | 6 | 64472191 |
Infusion related reaction | 23.33 | 11.29 | 20 | 26515 | 164447 | 64307750 |
Device delivery system issue | 23.12 | 11.29 | 8 | 26527 | 398 | 64471799 |
Product container issue | 23.01 | 11.29 | 10 | 26525 | 921 | 64471276 |
Cardiac death | 22.58 | 11.29 | 11 | 26524 | 1317 | 64470880 |
Testicular pain | 22.42 | 11.29 | 12 | 26523 | 1748 | 64470449 |
Intentional product misuse | 22.32 | 11.29 | 73 | 26462 | 72222 | 64399975 |
Renal artery thrombosis | 22.26 | 11.29 | 8 | 26527 | 445 | 64471752 |
Product complaint | 22.22 | 11.29 | 26 | 26509 | 11928 | 64460269 |
Hypogonadism male | 22.20 | 11.29 | 6 | 26529 | 128 | 64472069 |
Hyperhidrosis | 22.19 | 11.29 | 106 | 26429 | 124814 | 64347383 |
Gender dysphoria | 21.92 | 11.29 | 5 | 26530 | 51 | 64472146 |
Growth hormone-producing pituitary tumour | 21.92 | 11.29 | 5 | 26530 | 51 | 64472146 |
Vaginal disorder | 21.45 | 11.29 | 8 | 26527 | 495 | 64471702 |
Insulin resistance | 21.41 | 11.29 | 10 | 26525 | 1090 | 64471107 |
Dissociative identity disorder | 21.26 | 11.29 | 5 | 26530 | 59 | 64472138 |
Product physical consistency issue | 21.16 | 11.29 | 8 | 26527 | 514 | 64471683 |
Coronary artery occlusion | 20.65 | 11.29 | 27 | 26508 | 13864 | 64458333 |
Spontaneous cerebrospinal fluid leak syndrome | 20.39 | 11.29 | 3 | 26532 | 0 | 64472197 |
Hyperoestrogenism | 20.39 | 11.29 | 3 | 26532 | 0 | 64472197 |
Renal artery fibromuscular dysplasia | 20.39 | 11.29 | 3 | 26532 | 0 | 64472197 |
Suicidal ideation | 20.37 | 11.29 | 67 | 26468 | 66475 | 64405722 |
Cardiomyopathy | 20.29 | 11.29 | 37 | 26498 | 25319 | 64446878 |
Impulsive behaviour | 20.26 | 11.29 | 13 | 26522 | 2650 | 64469547 |
Phaeochromocytoma | 20.22 | 11.29 | 8 | 26527 | 581 | 64471616 |
Renal cell carcinoma | 19.97 | 11.29 | 18 | 26517 | 6086 | 64466111 |
Lower respiratory tract infection | 19.93 | 11.29 | 7 | 26528 | 94607 | 64377590 |
Blood growth hormone increased | 19.80 | 11.29 | 8 | 26527 | 614 | 64471583 |
Acne conglobata | 19.71 | 11.29 | 4 | 26531 | 22 | 64472175 |
Thrombocytopenia | 19.62 | 11.29 | 39 | 26496 | 223762 | 64248435 |
Anaemia | 19.39 | 11.29 | 85 | 26450 | 378595 | 64093602 |
Cortisol increased | 18.75 | 11.29 | 7 | 26528 | 434 | 64471763 |
Pyrexia | 18.65 | 11.29 | 144 | 26391 | 558500 | 63913697 |
Needle issue | 18.64 | 11.29 | 21 | 26514 | 9251 | 64462946 |
Stomatitis | 18.60 | 11.29 | 11 | 26524 | 109594 | 64362603 |
Implant site bruising | 18.57 | 11.29 | 6 | 26529 | 241 | 64471956 |
Application site inflammation | 18.41 | 11.29 | 7 | 26528 | 457 | 64471740 |
Congestive cardiomyopathy | 18.40 | 11.29 | 22 | 26513 | 10322 | 64461875 |
Aggression | 18.34 | 11.29 | 51 | 26484 | 46181 | 64426016 |
Uterine cervical metaplasia | 18.31 | 11.29 | 3 | 26532 | 3 | 64472194 |
Oestrone increased | 18.31 | 11.29 | 3 | 26532 | 3 | 64472194 |
Death | 18.26 | 11.29 | 120 | 26415 | 482585 | 63989612 |
Drug withdrawal syndrome | 18.24 | 11.29 | 40 | 26495 | 31251 | 64440946 |
Drug intolerance | 18.04 | 11.29 | 31 | 26504 | 187961 | 64284236 |
Hypercoagulation | 17.99 | 11.29 | 12 | 26523 | 2611 | 64469586 |
Intraductal proliferative breast lesion | 17.61 | 11.29 | 11 | 26524 | 2140 | 64470057 |
Nasopharyngitis | 17.33 | 11.29 | 34 | 26501 | 196039 | 64276158 |
Stubbornness | 17.22 | 11.29 | 6 | 26529 | 305 | 64471892 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 17.20 | 11.29 | 10 | 26525 | 1709 | 64470488 |
Transient ischaemic attack | 16.80 | 11.29 | 48 | 26487 | 44134 | 64428063 |
Interstitial lung disease | 16.31 | 11.29 | 10 | 26525 | 97722 | 64374475 |
Pancytopenia | 16.31 | 11.29 | 21 | 26514 | 143288 | 64328909 |
Eye colour change | 16.10 | 11.29 | 6 | 26529 | 370 | 64471827 |
Septic shock | 15.98 | 11.29 | 12 | 26523 | 105425 | 64366772 |
Application site paraesthesia | 15.82 | 11.29 | 4 | 26531 | 65 | 64472132 |
Empty sella syndrome | 15.33 | 11.29 | 4 | 26531 | 74 | 64472123 |
Application site irritation | 15.32 | 11.29 | 9 | 26526 | 1567 | 64470630 |
Intentional overdose | 15.29 | 11.29 | 9 | 26526 | 89935 | 64382262 |
Wrong technique in product usage process | 15.26 | 11.29 | 60 | 26475 | 64914 | 64407283 |
Diastolic hypertension | 15.23 | 11.29 | 4 | 26531 | 76 | 64472121 |
Acromegaly | 15.04 | 11.29 | 4 | 26531 | 80 | 64472117 |
Product physical issue | 15.04 | 11.29 | 12 | 26523 | 3437 | 64468760 |
Bone marrow oedema syndrome | 14.71 | 11.29 | 3 | 26532 | 17 | 64472180 |
Hidradenitis | 14.41 | 11.29 | 10 | 26525 | 2319 | 64469878 |
Blood thyroid stimulating hormone decreased | 14.37 | 11.29 | 14 | 26521 | 5216 | 64466981 |
Retinal vein occlusion | 14.34 | 11.29 | 11 | 26524 | 2977 | 64469220 |
Thyrotoxic periodic paralysis | 14.31 | 11.29 | 4 | 26531 | 97 | 64472100 |
Mucosal inflammation | 14.31 | 11.29 | 4 | 26531 | 62580 | 64409617 |
Wolff-Parkinson-White syndrome | 14.26 | 11.29 | 5 | 26530 | 259 | 64471938 |
Amnesia | 14.24 | 11.29 | 48 | 26487 | 48221 | 64423976 |
Asthma exercise induced | 14.12 | 11.29 | 4 | 26531 | 102 | 64472095 |
Oxygen saturation decreased | 14.05 | 11.29 | 14 | 26521 | 107162 | 64365035 |
Nipple pain | 13.88 | 11.29 | 6 | 26529 | 545 | 64471652 |
Papilloedema | 13.77 | 11.29 | 14 | 26521 | 5491 | 64466706 |
Ovarian necrosis | 13.70 | 11.29 | 3 | 26532 | 25 | 64472172 |
Anorgasmia | 13.60 | 11.29 | 7 | 26528 | 942 | 64471255 |
Leukopenia | 13.53 | 11.29 | 13 | 26522 | 101229 | 64370968 |
Atrial fibrillation | 13.40 | 11.29 | 118 | 26417 | 170971 | 64301226 |
Device extrusion | 13.40 | 11.29 | 3 | 26532 | 28 | 64472169 |
Small airways disease | 13.40 | 11.29 | 3 | 26532 | 28 | 64472169 |
Angiofibroma | 13.22 | 11.29 | 4 | 26531 | 129 | 64472068 |
Factor V Leiden mutation | 13.22 | 11.29 | 4 | 26531 | 129 | 64472068 |
Ovarian cancer stage II | 13.21 | 11.29 | 3 | 26532 | 30 | 64472167 |
Malignant melanoma | 13.12 | 11.29 | 21 | 26514 | 12943 | 64459254 |
Melaena | 13.06 | 11.29 | 3 | 26532 | 53545 | 64418652 |
Hypothalamo-pituitary disorder | 12.97 | 11.29 | 7 | 26528 | 1037 | 64471160 |
Gastric hypomotility | 12.91 | 11.29 | 4 | 26531 | 140 | 64472057 |
Expired product administered | 12.79 | 11.29 | 14 | 26521 | 5973 | 64466224 |
Hepatic artery aneurysm | 12.71 | 11.29 | 3 | 26532 | 36 | 64472161 |
Pituitary tumour | 12.59 | 11.29 | 7 | 26528 | 1099 | 64471098 |
Nocturia | 12.57 | 11.29 | 19 | 26516 | 11146 | 64461051 |
Thalamic infarction | 12.55 | 11.29 | 7 | 26528 | 1105 | 64471092 |
Pericarditis | 12.54 | 11.29 | 5 | 26530 | 62511 | 64409686 |
Cardiovascular disorder | 12.49 | 11.29 | 23 | 26512 | 15858 | 64456339 |
Application site reaction | 12.39 | 11.29 | 6 | 26529 | 709 | 64471488 |
Prostatic disorder | 12.20 | 11.29 | 8 | 26527 | 1691 | 64470506 |
Renal embolism | 12.19 | 11.29 | 4 | 26531 | 169 | 64472028 |
Injection site pain | 12.15 | 11.29 | 83 | 26452 | 111325 | 64360872 |
Nephropathy | 12 | 11.29 | 16 | 26519 | 8370 | 64463827 |
Libido increased | 11.82 | 11.29 | 8 | 26527 | 1782 | 64470415 |
C-reactive protein increased | 11.76 | 11.29 | 13 | 26522 | 94896 | 64377301 |
Large intestine polyp | 11.58 | 11.29 | 18 | 26517 | 10819 | 64461378 |
Diabetes mellitus | 11.50 | 11.29 | 56 | 26479 | 66418 | 64405779 |
Astrocytoma | 11.45 | 11.29 | 4 | 26531 | 205 | 64471992 |
Malignant neoplasm progression | 11.39 | 11.29 | 18 | 26517 | 112853 | 64359344 |
Therapeutic response unexpected | 11.38 | 11.29 | 23 | 26512 | 16978 | 64455219 |
Fibromuscular dysplasia | 11.34 | 11.29 | 4 | 26531 | 211 | 64471986 |
Disease progression | 11.32 | 11.29 | 26 | 26509 | 141654 | 64330543 |
None
Source | Code | Description |
---|---|---|
ATC | G03BA03 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS 3-oxoandrosten (4) derivatives |
ATC | G03EA02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION Androgens and estrogens |
FDA CS | M0001109 | Androstanes |
FDA MoA | N0000000146 | Androgen Receptor Agonists |
MeSH PA | D000728 | Androgens |
MeSH PA | D006728 | Hormones |
FDA EPC | N0000175824 | Androgen |
CHEBI has role | CHEBI:50113 | androgene |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:83056 | Daphnia magna metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypogonadotropic hypogonadism | indication | 33927004 | |
Deficiency of testosterone biosynthesis | indication | 38825009 | |
Inhibition of lactation procedure | indication | 43141007 | |
Male hypogonadism | indication | 48723006 | |
Hypopituitarism | indication | 74728003 | DOID:9406 |
Menopausal flushing | indication | 198436008 | |
Undescended testicle | indication | 204878001 | DOID:11383 |
Bilateral orchidectomy | indication | 386634006 | |
Delayed puberty | indication | 400003000 | |
Klinefelter's syndrome, XXY | indication | 405769009 | |
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Primary Hypogonadism due to Bilateral Torsion | indication | ||
Primary Hypogonadism due to Orchitis | indication | ||
LHRH Deficiency | indication | ||
Chemotherapy-Induced Hypogonadism | indication | ||
Bilateral Anorchia | indication | ||
Noonan's syndrome | off-label use | 205824006 | DOID:3490 |
Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
Gynecomastia | contraindication | 4754008 | DOID:12698 |
Hypocalcemia | contraindication | 5291005 | |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Chloasma | contraindication | 36209000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Body fluid retention | contraindication | 43498006 | |
Thrombosis of retinal vein | contraindication | 46085004 | |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Chronic heart failure | contraindication | 48447003 | |
Dementia | contraindication | 52448006 | |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Heart disease | contraindication | 56265001 | DOID:114 |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Arteriosclerotic vascular disease | contraindication | 72092001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Breast lump | contraindication | 89164003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
Magnetic resonance imaging | contraindication | 113091000 | |
Neoplasm of liver | contraindication | 126851005 | DOID:3571 |
Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
Deep venous thrombosis | contraindication | 128053003 | |
Endometriosis | contraindication | 129103003 | |
Mammography abnormal | contraindication | 168750009 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Cerebrovascular accident | contraindication | 230690007 | |
Pulmonary thromboembolism | contraindication | 233935004 | |
Thrombophilia | contraindication | 234467004 | DOID:2452 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Edema | contraindication | 267038008 | |
Chorea | contraindication | 271700006 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Functional visual loss | contraindication | 313165001 | |
Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
Thromboembolic disorder | contraindication | 371039008 | |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Estrogen receptor positive tumor | contraindication | 416053008 | |
Family history of malignant neoplasm of breast | contraindication | 429740004 | |
Hypertensive urgency | contraindication | 443482000 | |
Carcinoma of female breast | contraindication | 447782002 | |
Smokes tobacco daily | contraindication | 449868002 | |
Breast Carcinoma in Males | contraindication |
Species | Use | Relation |
---|---|---|
Cattle | To increase rate of weight gain | Indication |
Cattle | To improve feed efficiency | Indication |
Product | Applicant | Ingredients |
---|---|---|
Component E-H with Tylan | Elanco US Inc. | 3 |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7608605 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7608606 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7608607 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7608608 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7608609 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7608610 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7935690 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 8063029 | April 21, 2023 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 8784878 | July 13, 2023 | A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE |
5.5MG/0.122GM ACTUATION | NATESTO | ACERUS | N205488 | May 28, 2014 | RX | GEL, METERED | NASAL | 8784882 | Feb. 4, 2024 | A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION. |
5.5MG/0.122GM ACTUATION | NATESTO | ACERUS | N205488 | May 28, 2014 | RX | GEL, METERED | NASAL | 8877230 | Feb. 4, 2024 | NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
50MG/5GM PACKET | TESTIM | AUXILIUM PHARMS LLC | N021454 | Oct. 31, 2002 | RX | GEL | TRANSDERMAL | 7320968 | Jan. 18, 2025 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 8993520 | June 2, 2026 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 9180194 | June 2, 2026 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF |
1.62% (20.25MG/1.25GM ACTUATION) | ANDROGEL | ABBVIE | N022309 | April 29, 2011 | RX | GEL, METERED | TRANSDERMAL | 8466137 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (20.25MG/1.25GM ACTUATION) | ANDROGEL | ABBVIE | N022309 | April 29, 2011 | RX | GEL, METERED | TRANSDERMAL | 8466138 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (20.25MG/1.25GM ACTUATION) | ANDROGEL | ABBVIE | N022309 | April 29, 2011 | RX | GEL, METERED | TRANSDERMAL | 8741881 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (20.25MG/1.25GM PACKET) | ANDROGEL | ABBVIE | N022309 | Sept. 7, 2012 | DISCN | GEL | TRANSDERMAL | 8466137 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (20.25MG/1.25GM PACKET) | ANDROGEL | ABBVIE | N022309 | Sept. 7, 2012 | DISCN | GEL | TRANSDERMAL | 8466138 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (20.25MG/1.25GM PACKET) | ANDROGEL | ABBVIE | N022309 | Sept. 7, 2012 | DISCN | GEL | TRANSDERMAL | 8741881 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (40.5MG/2.5GM PACKET) | ANDROGEL | ABBVIE | N022309 | Sept. 7, 2012 | DISCN | GEL | TRANSDERMAL | 8466137 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (40.5MG/2.5GM PACKET) | ANDROGEL | ABBVIE | N022309 | Sept. 7, 2012 | DISCN | GEL | TRANSDERMAL | 8466138 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
1.62% (40.5MG/2.5GM PACKET) | ANDROGEL | ABBVIE | N022309 | Sept. 7, 2012 | DISCN | GEL | TRANSDERMAL | 8741881 | Oct. 12, 2026 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 8419307 | Feb. 26, 2027 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 8807861 | Feb. 26, 2027 | A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT. |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 9289586 | Feb. 26, 2027 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF |
30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | AXIRON | ELI LILLY AND CO | N022504 | Nov. 23, 2010 | DISCN | SOLUTION, METERED | TRANSDERMAL | 8435944 | Sept. 27, 2027 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF |
12.5MG/1.25GM ACTUATION | VOGELXO | UPSHER SMITH LABS | N204399 | June 4, 2014 | RX | GEL, METERED | TRANSDERMAL | 8785426 | Feb. 11, 2034 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
12.5MG/1.25GM ACTUATION | VOGELXO | UPSHER SMITH LABS | N204399 | June 4, 2014 | RX | GEL, METERED | TRANSDERMAL | 9295675 | Feb. 11, 2034 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
12.5MG/1.25GM ACTUATION | VOGELXO | UPSHER SMITH LABS | N204399 | June 4, 2014 | RX | GEL, METERED | TRANSDERMAL | 9662340 | Feb. 11, 2034 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
50MG/5GM PACKET | VOGELXO | UPSHER SMITH LABS | N204399 | June 4, 2014 | RX | GEL | TRANSDERMAL | 8785426 | Feb. 11, 2034 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
50MG/5GM PACKET | VOGELXO | UPSHER SMITH LABS | N204399 | June 4, 2014 | RX | GEL | TRANSDERMAL | 9295675 | Feb. 11, 2034 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
50MG/5GM PACKET | VOGELXO | UPSHER SMITH LABS | N204399 | June 4, 2014 | RX | GEL | TRANSDERMAL | 9662340 | Feb. 11, 2034 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
5.5MG/0.122GM ACTUATION | NATESTO | ACERUS | N205488 | May 28, 2014 | RX | GEL, METERED | NASAL | 11090312 | March 17, 2034 | NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Androgen receptor | Nuclear hormone receptor | AGONIST | EC50 | 9.20 | WOMBAT-PK | CHEMBL | |||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 5.84 | DRUG MATRIX | |||||
Aromatase | Enzyme | Ki | 6.22 | CHEMBL | |||||
Corticosteroid-binding globulin | Secreted | Ki | 6.72 | CHEMBL | |||||
Sex hormone-binding globulin | Secreted | Kd | 9.20 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 4.30 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 5.92 | CHEMBL | |||||
Alpha-synuclein | Transporter | IC50 | 4.01 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 8.85 | CHEMBL | |||||
Progesterone receptor | Transcription factor | Ki | 6.60 | DRUG MATRIX | |||||
C-8 sterol isomerase | Enzyme | Ki | 5.11 | CHEMBL | |||||
Steroid 5-alpha-reductase | Enzyme | IC50 | 5.72 | CHEMBL | |||||
Constitutive androstane receptor | Nuclear hormone receptor | IC50 | 4.52 | CHEMBL |
ID | Source |
---|---|
4017484 | VUID |
N0000145872 | NUI |
D00075 | KEGG_DRUG |
4017484 | VANDF |
C0039601 | UMLSCUI |
CHEBI:17347 | CHEBI |
TES | PDB_CHEM_ID |
CHEMBL386630 | ChEMBL_ID |
CHEMBL1201101 | ChEMBL_ID |
DB00624 | DRUGBANK_ID |
D013739 | MESH_DESCRIPTOR_UI |
6013 | PUBCHEM_CID |
2858 | IUPHAR_LIGAND_ID |
1900 | INN_ID |
3XMK78S47O | UNII |
10379 | RXNORM |
2966 | MMSL |
5552 | MMSL |
d00558 | MMSL |
001245 | NDDF |
109033004 | SNOMEDCT_US |
43688007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Androderm | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5990 | PATCH | 2 mg | TRANSDERMAL | NDA | 34 sections |
Androderm | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5992 | PATCH | 4 mg | TRANSDERMAL | NDA | 34 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8425 | GEL | 10 mg | TRANSDERMAL | NDA | 37 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8450 | GEL | 10 mg | TRANSDERMAL | NDA | 37 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8462 | GEL | 16.20 mg | TRANSDERMAL | NDA | 37 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0051-8488 | GEL | 10 mg | TRANSDERMAL | NDA | 37 sections |
Vogelxo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0871 | GEL | 50 mg | TOPICAL | NDA | 37 sections |
Vogelxo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0245-0872 | GEL, METERED | 12.50 mg | TOPICAL | NDA | 37 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2114 | SOLUTION | 30 mg | TOPICAL | ANDA | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2363 | GEL, METERED | 10 mg | TOPICAL | ANDA | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2921 | GEL | 10 mg | TOPICAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2924 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2925 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2926 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3216 | GEL | 10 mg | TOPICAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3217 | GEL | 10 mg | TOPICAL | ANDA | 32 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3524 | GEL | 50 mg | TRANSDERMAL | ANDA | 30 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3524 | GEL | 50 mg | TRANSDERMAL | ANDA | 30 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-7831 | GEL, METERED | 10 mg | TOPICAL | NDA authorized generic | 33 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1120 | GEL | 50 mg | TOPICAL | NDA authorized generic | 35 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1121 | GEL, METERED | 12.50 mg | TOPICAL | NDA authorized generic | 35 sections |
Testim | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-853 | GEL | 50 mg | TOPICAL | NDA | 13 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-967 | GEL | 20.25 mg | TOPICAL | ANDA | 33 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-968 | GEL | 20.25 mg | TOPICAL | ANDA | 33 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-969 | GEL | 40.50 mg | TOPICAL | ANDA | 33 sections |
Androgel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-112 | GEL | 10 mg | TRANSDERMAL | NDA | 18 sections |
Testosterone Gel, 1% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-019 | GEL | 10 mg | TRANSDERMAL | ANDA | 34 sections |
Testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-078 | GEL | 16.20 mg | TRANSDERMAL | ANDA | 29 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-130 | SOLUTION | 30 mg | TOPICAL | ANDA | 32 sections |
testosterone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-130 | SOLUTION | 30 mg | TOPICAL | ANDA | 32 sections |